A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
Public ClinicalTrials.gov record NCT02443155. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function
Study identification
- NCT ID
- NCT02443155
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 308 participants
Conditions and interventions
Conditions
Interventions
- NNC0114-0006 Drug
- liraglutide Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 9, 2015
- Primary completion
- Aug 30, 2018
- Completion
- Feb 26, 2019
- Last update posted
- Apr 8, 2021
2015 – 2019
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | La Jolla | California | 92037 | — |
| Novo Nordisk Investigational Site | Northridge | California | 91325 | — |
| Novo Nordisk Investigational Site | Aurora | Colorado | 80045 | — |
| Novo Nordisk Investigational Site | Miami | Florida | 33136 | — |
| Novo Nordisk Investigational Site | Orlando | Florida | 32804 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30318 | — |
| Novo Nordisk Investigational Site | Lexington | Kentucky | 40503 | — |
| Novo Nordisk Investigational Site | Las Vegas | Nevada | 89128 | — |
| Novo Nordisk Investigational Site | Teaneck | New Jersey | 07666 | — |
| Novo Nordisk Investigational Site | Chapel Hill | North Carolina | 27517 | — |
| Novo Nordisk Investigational Site | Nashville | Tennessee | 37203 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77079 | — |
| Novo Nordisk Investigational Site | Mesquite | Texas | 75149 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02443155, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2021 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02443155 live on ClinicalTrials.gov.